免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / Dexmetomidine in Children Undergoing General Anaesthesia

Dexmetomidine in Children Undergoing General Anaesthesia

Study Description
Brief Summary:
The effects of dexmedetomidine on the onset of both the general anaesthesia induction and the neuromuscular blockade in children of school age will be investigated. Ten minutes before the induction of general anaesthesia, the first group will receive continuous infusion of dexmedetomidine (DEX group), while the second group will receive normal saline (Placebo group).

Condition or disease Intervention/treatment Phase
Anesthesia Drug: Dexmedetomidine Other: 0.9% saline Not Applicable

Show Show detailed description
Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description: Single (Outcomes Assessor)
Primary Purpose: Other
Official Title: The Effects of Dexmedetomidine on Induction of Anaesthesia and Onset of Neuromuscular Blockade in Children
Actual Study Start Date : May 2, 2019
Actual Primary Completion Date : March 20, 2020
Actual Study Completion Date : September 25, 2020
Arms and Interventions
Arm Intervention/treatment
Active Comparator: Dexmedetomidine

Drug: dexmedetomidine (Dexmed) solution(100μcg of dexmedetomidine in 50ml N/S 0.9%). given at a bolus dose of 0.5μcg/kg of the dexmedetomidine solution [that corresponds to the volume (ml) calculated by the type "body weight (Kg)/4 or body weight (Kg) X 0.25".

THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY

Drug: Dexmedetomidine
INFUSION BEFORE INDUCTION OF ANAESTHESIA
Other Name: Dexmed

Placebo Comparator: 0.9 % saline
Drug:0.9 % saline solution (Normal saline) given at a volume (ml) determined by the type: "body weight (Kg)/4 or body weight (Kg) X 0.25" THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY
Other: 0.9% saline
INFUSION BEFORE INDUCTION OF ANAESTHESIA
Other Name: normal saline

Outcome Measures
Primary Outcome Measures :
  1. Onset of neuromuscular blockade [ Time Frame: Up to 5 minutes after the injection of rocuronium ]
    Neuromuscular blockade is estimated with TOF acceleromyography, while onset of neuromuscular blockaded is defined as the time needed to achieve TOF=0 after the injection of rocuronium.


Secondary Outcome Measures :
  1. Onset of anaesthesia induction [ Time Frame: Up to 15 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively ]
    The depth of anaesthesia is monitored using the BIS device (range 0-100). Onset of anesthesia is defined as the time needed to achieve BIS value<60, after the injection of propofol.

  2. Number of participants who developed bradycardia [ Time Frame: Up to 30 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively ]
    Bradycardia is defined as >20% reduction of HR from the baseline values or as HR<60bpm using ECG monitoring.

  3. Number of participants who developed hypotension [ Time Frame: Up to 30 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively ]
    Hypotension is defined as >20mmHg reduction of SAP from the baseline values using noninvasive monitoring of arterial pressure


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   4 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • children underoing elective surgery under general anaesthsia
  • age 4-12 years old
  • ASA I-II

Exclusion Criteria:

  • patient or parent refusal
  • Mallampati score> 3
  • BMI>35
  • severe systemic cardiac disease
  • neuromuscular disease
  • recent respiratory infection
  • drug allergy
Contacts and Locations

Locations
Layout table for location information
Greece
2nd Department of Anesthesiology, Attikon University Hospital
Athens, Attiki, Greece, 12462
Sponsors and Collaborators
Attikon Hospital
Investigators
Layout table for investigator information
Study Chair: Georgia K Kostopanagiotou 2nd Department of Anaesthesiology, "Attikon" University Hospital
Principal Investigator: Paraskevi K Matsota 2nd Department of Anaesthesiology, "Attikon" University Hospital
Tracking Information
First Submitted Date  ICMJE April 16, 2019
First Posted Date  ICMJE April 22, 2019
Last Update Posted Date November 6, 2020
Actual Study Start Date  ICMJE May 2, 2019
Actual Primary Completion Date March 20, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 18, 2019)
Onset of neuromuscular blockade [ Time Frame: Up to 5 minutes after the injection of rocuronium ]
Neuromuscular blockade is estimated with TOF acceleromyography, while onset of neuromuscular blockaded is defined as the time needed to achieve TOF=0 after the injection of rocuronium.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 18, 2019)
  • Onset of anaesthesia induction [ Time Frame: Up to 15 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively ]
    The depth of anaesthesia is monitored using the BIS device (range 0-100). Onset of anesthesia is defined as the time needed to achieve BIS value<60, after the injection of propofol.
  • Number of participants who developed bradycardia [ Time Frame: Up to 30 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively ]
    Bradycardia is defined as >20% reduction of HR from the baseline values or as HR<60bpm using ECG monitoring.
  • Number of participants who developed hypotension [ Time Frame: Up to 30 minutes after the initiation of the infusion of dexmedemoditine or normal saline, respectively ]
    Hypotension is defined as >20mmHg reduction of SAP from the baseline values using noninvasive monitoring of arterial pressure
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Dexmetomidine in Children Undergoing General Anaesthesia
Official Title  ICMJE The Effects of Dexmedetomidine on Induction of Anaesthesia and Onset of Neuromuscular Blockade in Children
Brief Summary The effects of dexmedetomidine on the onset of both the general anaesthesia induction and the neuromuscular blockade in children of school age will be investigated. Ten minutes before the induction of general anaesthesia, the first group will receive continuous infusion of dexmedetomidine (DEX group), while the second group will receive normal saline (Placebo group).
Detailed Description

Children 4 to 12 years old, ASA I-II, scheduled for elective minor or medium procedure under general anaesthesia will be included in the study, after written informed concern from their parents has been obtained. Participants will be randomly allocated according to the type of the solution infused 10 minutes before the induction of general anaesthesia into one of the following two groups using the closed envelop method.

DEX group: patients will receive 0.5μcg/kg IV bolus of dexmedetomidine in 10 min, right before the induction of general anaesthesia. The concentration of dexmedetomidine solution is 0.2μcg/ml, (100μcg of dexmedetomidine are diluted in 50ml N/S 0.9%), which corresponds to volume (ml) calculated by the type: "body weight (Kg)/4 or body weight (Kg) X 0.25".

Placebo group: patients will receive N/S 0.9% IV in 10 min, right before the induction of general anaesthesia. The volume infused (ml) is determined by the same type: "body weight (Kg)/4 or body weight (Kg) X 0.25".

The above solutions will be prepared by the anaesthetist who will provide the anaesthesia and will not be known to the anaesthetist who will record the study's measurements.

No premedication will be given. All children will receive the same anaesthesia induction scheme.

Once the patients have entered the operating theater, standard monitoring will be applied (NIBP, ECG, SpO2) and an IV line will be inserted. Depth of anaesthesia and monitoring of neuromuscular blockade will be recorded by BIS and TOF, respectively. Afterwards continues infusion of dexmedetomidine or N/S 0.9% will be initiated, depending on the assigned group, for duration of 10 min.

Right after the end of the infusion, we will proceed to the induction of anaesthesia with 3mg/kg of propofol and 2μcg/kg of fentanyl and when BIS<60 will be achieved, rocuronium will be administered at a dose of 0.7 mg/kg . Right afterwards, neuromuscular blockade will be estimated using the TOF acceleromyography (4 supramaximal twitches, 0.5sec interval in 2sec, frequency 2Hz, intensity 50mA). TOF will be repeated every 15sec. At the same time, ventilation of the patient will be supported with a bag and mask (Ο2 100%). When TOF=0 will be achieved, the patient will be intubated. After intubation, anaesthesia will be maintained with sevoflurane 1 MAC in 50% O2/Air.

The intubation conditions will be estimated using the Viby-Mogensen score (scale of 5 parameters). Also, number of intubation attempts will be recorded.

The study period is from "right before the start" of the dexmedetomidine or the N/S 0.9% infusion up to 5 min after the tracheal intubation. The following time points will be recorded:

Start time of the IV infusion of dexmedetomidine or N/S 0.9% (tstart) End time of the IV infusion of dexmedetomidine or N/S 0.9% (tend) Time of propofol injection (tprop) Time of achieving BIS<60 (tBIS<60) Time from propofol injection to achieve BIS<60 (tprop - tBIS<60) in min Time of rocuronium injection (troc) Time of achieving TOF=0 (tTOF=0) Time from rocuronium injection to TOF=0 (troc - tTOF=0) in min Time that intubation performed (tintubation)

Measurements Heart rate (HR), systolic arterial pressure (SAP), SpO2 and BIS will be recorded at the following time points: just before the start of infusion of dexmedetomidine or N/S 0.9% (tbaseline) and afterwards every 3 min during the infusion, as well as at the particular time points tend, tprop, tBIS<60, troc, tTOF=0, tintubation and 5 min after the intubation. Viby-Mogensen score and number of intubation attempts will also be recorded.

During the study period, any adverse effects or incidences like respiratory depression during the 10 min infusion of the study solutions, bradycardia (defined as >20% reduction of HR from the baseline values or as HR<60bpm), hypotension (defined as >20mmHg reduction of SAP from the baseline values), allergic reactions, bronchospasm and laryngospasm will be recorded. In case of bradycardia or hypotension, IV atropine 0.02μcg/kg or ephedrine 1-2μcg/kg will be administered, respectively. In case of persistent bradycardia despite the use of atropine, dexmedetomidine infusion will be stopped and the child will be excluded from the study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description:
Single (Outcomes Assessor)
Primary Purpose: Other
Condition  ICMJE Anesthesia
Intervention  ICMJE
  • Drug: Dexmedetomidine
    INFUSION BEFORE INDUCTION OF ANAESTHESIA
    Other Name: Dexmed
  • Other: 0.9% saline
    INFUSION BEFORE INDUCTION OF ANAESTHESIA
    Other Name: normal saline
Study Arms  ICMJE
  • Active Comparator: Dexmedetomidine

    Drug: dexmedetomidine (Dexmed) solution(100μcg of dexmedetomidine in 50ml N/S 0.9%). given at a bolus dose of 0.5μcg/kg of the dexmedetomidine solution [that corresponds to the volume (ml) calculated by the type "body weight (Kg)/4 or body weight (Kg) X 0.25".

    THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY

    Intervention: Drug: Dexmedetomidine
  • Placebo Comparator: 0.9 % saline
    Drug:0.9 % saline solution (Normal saline) given at a volume (ml) determined by the type: "body weight (Kg)/4 or body weight (Kg) X 0.25" THE SOLUTION IS GIVEN AS CONTINUOUS INFUSION 10 MINUTES BEFORE THE INDUCTION OF GENERAL ANAESTHESIA IN CHILDREN UNDERGOING ELECTIVE SURGERY
    Intervention: Other: 0.9% saline
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 18, 2019)
60
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE September 25, 2020
Actual Primary Completion Date March 20, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • children underoing elective surgery under general anaesthsia
  • age 4-12 years old
  • ASA I-II

Exclusion Criteria:

  • patient or parent refusal
  • Mallampati score> 3
  • BMI>35
  • severe systemic cardiac disease
  • neuromuscular disease
  • recent respiratory infection
  • drug allergy
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 4 Years to 12 Years   (Child)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Greece
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03923075
Other Study ID Numbers  ICMJE DEXAINMBCH
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Plan Description: restrictions due to regulation for personal data protection
Responsible Party Paraskevi Matsota, Attikon Hospital
Study Sponsor  ICMJE Attikon Hospital
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Chair: Georgia K Kostopanagiotou 2nd Department of Anaesthesiology, "Attikon" University Hospital
Principal Investigator: Paraskevi K Matsota 2nd Department of Anaesthesiology, "Attikon" University Hospital
PRS Account Attikon Hospital
Verification Date November 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP